Contract Development and Manufacturing Organization (CDMO) / Pharmaceutical Services
Strategic Profile
Siegfried continues to strengthen its manufacturing capabilities in the rapidly growing cell and gene therapy market, with its completed facility Dinamiqs enabling end-to-end manufacturing of viral vector gene therapies. The company has a large global footprint with 13 production sites on three continents. The EVOLVE+ strategy and strategic M&A activities are set to enhance growth, expand services, and improve margins, with investments in new technologies and diversification expected to drive revenue stability and efficiency improvements.
Cyborg Score Rationale
In 2024, revenue grew 1.82% to 1.29 billion, with earnings increasing 41.93% to 160.06 million, demonstrating operational leverage. The long-term outlook appears bright as biotechnology and pharmaceutical firms will be more reliant on outsourced manufacturing. However, the company is vulnerable to facility closures and regulatory warnings that could result in manufacturing delays.
Top Insights
Cell and gene therapy manufacturing through Dinamiqs facility positions Siegfried for high-margin future growth